Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other STIs Clear all
Completed Phase 3 Interventional

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

NCT00002178
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Not listed Phase 3 Interventional

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

NCT00007436
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

NCT00002425
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

NCT00029341
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Youth to Text or Telehealth for Engagement in HIV Care

NCT03681145
View directory record Official record
Conditions
HIV/AIDS, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Depression, Substance Use
Interventions
Counselor delivered telehealth intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

NCT01193842
View directory record Official record
Conditions
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, HIV Infection, Plasmablastic Lymphoma, Primary Effusion Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
35
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

NCT00002162
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

NCT00002328
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

NCT00445146
View directory record Official record
Conditions
HIV Infections
Interventions
EVG, RTV, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
47
States / cities
Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

NCT01422330
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Etravirine
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Beverly Hills, California • North Hollywood, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Not applicable Interventional

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002401
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

NCT00183456
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Peer-oriented intervention, Group cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 74 Years
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 5, 2026, 2:27 AM EDT
Not listed Phase 1 Interventional

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

NCT00006209
View directory record Official record
Conditions
HIV Infections
Interventions
Tucaresol
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness of Individual Versus Group-Level Interventions to Increase PrEP Uptake and Reduce HIV/STI Incidence

NCT06022809
View directory record Official record
Conditions
HIV, Other STIs
Interventions
Dada Kwa Dada (individual-level), DADA (group-level)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Roxbury, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 5, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

NCT00002442
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Using Heavy Water to Study Cell Dynamics in Parkinson's Disease

NCT00990379
View directory record Official record
Conditions
Parkinson's Disease, HIV Infections
Interventions
Not listed
Lead sponsor
Salena Killion
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

NCT00001095
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 5, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

NCT00012519
View directory record Official record
Conditions
HIV Infections
Interventions
indinavir sulfate, ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 5, 2026, 2:27 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 2:27 AM EDT